Safety of entacapone and apomorphine coadministration in levodopa‐treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double‐blind, placebo‐controlled, cross‐over study
Identifieur interne : 001991 ( Main/Curation ); précédent : 001990; suivant : 001992Safety of entacapone and apomorphine coadministration in levodopa‐treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double‐blind, placebo‐controlled, cross‐over study
Auteurs : Jan C. M. Zijlmans [Royaume-Uni, Pays-Bas] ; Berengere Debilly [France] ; Olivier Rascol [France] ; Andrew J. Lees [Royaume-Uni] ; Franck Durif [France]Source :
- Movement Disorders [ 0885-3185 ] ; 2004-09.
English descriptors
- KwdEn :
Abstract
We investigated whether administration of the catechol‐O‐methyl transferase (COMT) inhibitor entacapone, at doses of 200 mg and 400 mg, alters the pharmacokinetics of apomorphine in Parkinson's disease patients experiencing severe motor fluctuations. In addition, the pharmacodynamics and safety of entacapone and apomorphine coadministration in these patients were examined. The study followed a three‐sequence, three‐period, crossover design. Patients were randomly assigned to one of three sequences that included single oral doses of entacapone 200 mg, entacapone 400 mg, and placebo in a predefined order. On 3 separate test days, study treatment was administered before apomorphine. The study evaluations (pharmacokinetics, tapping test, and dyskinesia evaluation [Abnormal Involuntary Movements Scale ‐ AIMS]) were performed on these days. Furthermore, Unified Parkinson Disease Rating Scale (UPDRS) scores were evaluated at baseline and study end. Pharmacokinetic parameters for apomorphine (Cmax, AUC, tmax, t1/2) were unchanged by the administration of entacapone, and changes in both the tapping test and AIMS score were similar with all treatments (entacapone 200 mg, entacapone 400 mg, and placebo). There was no significant difference in mean total UPDRS scores between baseline and study end. The administration of entacapone did not change the pharmacokinetic or pharmacodynamic effects of apomorphine in these patients or prolong the clinical effect of apomorphine. Thus, apomorphine may be safely administered to patients receiving therapy with levodopa and entacapone, providing a useful addition to treatment for patients with advanced Parkinson's disease. © 2004 Movement Disorder Society
Url:
DOI: 10.1002/mds.20188
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001C63
Links to Exploration step
ISTEX:33C304CDCF0DAA03F87B5679B68534652078FFEALe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Safety of entacapone and apomorphine coadministration in levodopa‐treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double‐blind, placebo‐controlled, cross‐over study</title><author><name sortKey="Zijlmans, Jan C M" sort="Zijlmans, Jan C M" uniqKey="Zijlmans J" first="Jan C. M." last="Zijlmans">Jan C. M. Zijlmans</name><affiliation wicri:level="1"><mods:affiliation>National Hospital for Neurology and Neurosurgery, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>National Hospital for Neurology and Neurosurgery, London</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Reta Lila Weston Institute of Neurological Studies, University College London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Reta Lila Weston Institute of Neurological Studies, University College London</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, VU University Medical Centre, Amsterdam, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Neurology, VU University Medical Centre, Amsterdam</wicri:regionArea></affiliation></author><author><name sortKey="Debilly, Berengere" sort="Debilly, Berengere" uniqKey="Debilly B" first="Berengere" last="Debilly">Berengere Debilly</name><affiliation wicri:level="1"><mods:affiliation>Federation de Neurologie, Hopital Gabriel Montpied, Clermont Ferrand, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Federation de Neurologie, Hopital Gabriel Montpied, Clermont Ferrand</wicri:regionArea></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><mods:affiliation>Clinical Investigation Centre, Department of Clinical Pharmacology, INSERM U 455, Toulouse University Hospital, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Clinical Investigation Centre, Department of Clinical Pharmacology, INSERM U 455, Toulouse University Hospital</wicri:regionArea></affiliation></author><author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew J. Lees</name><affiliation wicri:level="1"><mods:affiliation>National Hospital for Neurology and Neurosurgery, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>National Hospital for Neurology and Neurosurgery, London</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Reta Lila Weston Institute of Neurological Studies, University College London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Reta Lila Weston Institute of Neurological Studies, University College London</wicri:regionArea></affiliation></author><author><name sortKey="Durif, Franck" sort="Durif, Franck" uniqKey="Durif F" first="Franck" last="Durif">Franck Durif</name><affiliation wicri:level="1"><mods:affiliation>Federation de Neurologie, Hopital Gabriel Montpied, Clermont Ferrand, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Federation de Neurologie, Hopital Gabriel Montpied, Clermont Ferrand</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:33C304CDCF0DAA03F87B5679B68534652078FFEA</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1002/mds.20188</idno><idno type="url">https://api.istex.fr/document/33C304CDCF0DAA03F87B5679B68534652078FFEA/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001C63</idno><idno type="wicri:Area/Main/Curation">001991</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Safety of entacapone and apomorphine coadministration in levodopa‐treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double‐blind, placebo‐controlled, cross‐over study</title><author><name sortKey="Zijlmans, Jan C M" sort="Zijlmans, Jan C M" uniqKey="Zijlmans J" first="Jan C. M." last="Zijlmans">Jan C. M. Zijlmans</name><affiliation wicri:level="1"><mods:affiliation>National Hospital for Neurology and Neurosurgery, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>National Hospital for Neurology and Neurosurgery, London</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Reta Lila Weston Institute of Neurological Studies, University College London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Reta Lila Weston Institute of Neurological Studies, University College London</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, VU University Medical Centre, Amsterdam, The Netherlands</mods:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Neurology, VU University Medical Centre, Amsterdam</wicri:regionArea></affiliation></author><author><name sortKey="Debilly, Berengere" sort="Debilly, Berengere" uniqKey="Debilly B" first="Berengere" last="Debilly">Berengere Debilly</name><affiliation wicri:level="1"><mods:affiliation>Federation de Neurologie, Hopital Gabriel Montpied, Clermont Ferrand, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Federation de Neurologie, Hopital Gabriel Montpied, Clermont Ferrand</wicri:regionArea></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><mods:affiliation>Clinical Investigation Centre, Department of Clinical Pharmacology, INSERM U 455, Toulouse University Hospital, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Clinical Investigation Centre, Department of Clinical Pharmacology, INSERM U 455, Toulouse University Hospital</wicri:regionArea></affiliation></author><author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew J. Lees</name><affiliation wicri:level="1"><mods:affiliation>National Hospital for Neurology and Neurosurgery, London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>National Hospital for Neurology and Neurosurgery, London</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Reta Lila Weston Institute of Neurological Studies, University College London, United Kingdom</mods:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Reta Lila Weston Institute of Neurological Studies, University College London</wicri:regionArea></affiliation></author><author><name sortKey="Durif, Franck" sort="Durif, Franck" uniqKey="Durif F" first="Franck" last="Durif">Franck Durif</name><affiliation wicri:level="1"><mods:affiliation>Federation de Neurologie, Hopital Gabriel Montpied, Clermont Ferrand, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Federation de Neurologie, Hopital Gabriel Montpied, Clermont Ferrand</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-09">2004-09</date><biblScope unit="volume">19</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1006">1006</biblScope><biblScope unit="page" to="1011">1011</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">33C304CDCF0DAA03F87B5679B68534652078FFEA</idno><idno type="DOI">10.1002/mds.20188</idno><idno type="ArticleID">MDS20188</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>apomorphine</term><term>entacapone</term><term>levodopa</term><term>pharmacokinetics</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We investigated whether administration of the catechol‐O‐methyl transferase (COMT) inhibitor entacapone, at doses of 200 mg and 400 mg, alters the pharmacokinetics of apomorphine in Parkinson's disease patients experiencing severe motor fluctuations. In addition, the pharmacodynamics and safety of entacapone and apomorphine coadministration in these patients were examined. The study followed a three‐sequence, three‐period, crossover design. Patients were randomly assigned to one of three sequences that included single oral doses of entacapone 200 mg, entacapone 400 mg, and placebo in a predefined order. On 3 separate test days, study treatment was administered before apomorphine. The study evaluations (pharmacokinetics, tapping test, and dyskinesia evaluation [Abnormal Involuntary Movements Scale ‐ AIMS]) were performed on these days. Furthermore, Unified Parkinson Disease Rating Scale (UPDRS) scores were evaluated at baseline and study end. Pharmacokinetic parameters for apomorphine (Cmax, AUC, tmax, t1/2) were unchanged by the administration of entacapone, and changes in both the tapping test and AIMS score were similar with all treatments (entacapone 200 mg, entacapone 400 mg, and placebo). There was no significant difference in mean total UPDRS scores between baseline and study end. The administration of entacapone did not change the pharmacokinetic or pharmacodynamic effects of apomorphine in these patients or prolong the clinical effect of apomorphine. Thus, apomorphine may be safely administered to patients receiving therapy with levodopa and entacapone, providing a useful addition to treatment for patients with advanced Parkinson's disease. © 2004 Movement Disorder Society</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001991 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 001991 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Curation
|type= RBID
|clé= ISTEX:33C304CDCF0DAA03F87B5679B68534652078FFEA
|texte= Safety of entacapone and apomorphine coadministration in levodopa‐treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double‐blind, placebo‐controlled, cross‐over study
}}
| This area was generated with Dilib version V0.6.23. |  |